Live Breaking News & Updates on பாஸ்கல் நீகெண்

Stay updated with breaking news from பாஸ்கல் நீகெண். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 Results


Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 Results
OVERVIEW
The Company reported a net loss and total comprehensive loss of $2,554,000 and $5,268,000 for the three and nine-month periods ended April 30, 2021. For the three and nine-month periods ended April 30, 2020, net loss and total comprehensive loss totalled $2,489,000 and $6,896,000, respectively. The net loss and total comprehensive loss for the three-month period ending April 30, 2021, includes a net loss of $nil (2020 - $198,000) and for the nine-month period ending April 30, 2021 a gain of $1,536,000 (2020 - loss of $465,000) from discontinued operations. The Company lost control of its subsidiary in Poland during the three-month period ending October 31, 2020 though continued to exert significant influence until December 22, 2020 when the Company disposed of its remaining interest for gross proceeds of $2,308,000. ....

Richmond Hill , Frank Michalargias , Pascal Nigen , Helix Biopharma Corp , Company Interim Condensed Statement Of Financial Position , Company Interim Condensed Financial , Fund Management , Moffit Cancer Centre , Alpha Bronze , Company Interim Condensed Statement Of Net Loss , Lind Global Macro Fund , Helix Biopharma , Investigational New Drug , Multijurisdictional Disclosure System , Accounting Oversight Board , Consulting Management , Convertible Security , Interim Condensed Statement , Net Loss , Comprehensive Loss , Condensed Statements , Financial Position , Interim Condensed Financial Statements , Chief Financial , Looking Statements , Annual Information Form ,

Helix BioPharma Corp. Announces Institutional Investment for Gross Proceeds of up to CAD$10 million


Helix BioPharma Corp. Announces Institutional Investment for Gross Proceeds of up to CAD$10 million
RICHMOND HILL, ON / ACCESSWIRE / May 11, 2021 / Helix BioPharma Corp.(TSX:HBP)( Helix or the Company ), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive convertible security funding agreement (the Agreement ) with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC (together, Lind ). Under the terms of the Agreement, an initial CAD$3.5 million will be funded pursuant to the issuance of a convertible security (a Convertible Security ) which is expected to occur on or around May 12, 2021 ( First Tranche ). The Agreement also contemplates the issuance of a second Convertible Security upon the mutual agreement of the Company and Lind for gross proceeds to the Company of up to CAD$6.5 million (the Second Tranc ....

New York , United States , United Kingdom , Richmond Hill , Frank Michalargias , Pascal Nigen , Company Common , Alpha Bronze , Toronto Stock Exchange , Helix Biopharma Corp , Lind Partners , Lind Global Macro Fund , Convertible Security , First Tranche , Second Tranche , Convertible Securities , Common Shares , Common Share , Toronto Stock , Chief Financial , Looking Statements , Annual Information Form , Helix Biopharma , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் ,